Evidence map›Paper›PMID 30974891›Full record

ArticleVaccines2019

New Promising Targets for Synthetic Omptin-Based Peptide Vaccine against Gram-Negative Pathogens.

Valentina A Feodorova, Anna M Lyapina, Sergey S Zaitsev, Maria A Khizhnyakova, Lidiya V Sayapina, Onega V Ulianova, Sergey S Ulyanov, Vladimir L Motin

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Pathogenic signature of invasive non-typhoidalHuman vaccines & immunotherapeutics · 2020
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Valentina A FeodorovaLaboratory for Molecular Biology and NanoBiotechnology, Federal Research Center for Virology and Microbiology, Branch in Saratov, 410028 Saratov, Russia. feodorovav@mail.ru.
Anna M LyapinaLaboratory for Molecular Biology and NanoBiotechnology, Federal Research Center for Virology and Microbiology, Branch in Saratov, 410028 Saratov, Russia. lyapina_anna@inbox.ru.
Sergey S ZaitsevLaboratory for Molecular Biology and NanoBiotechnology, Federal Research Center for Virology and Microbiology, Branch in Saratov, 410028 Saratov, Russia. zaytsev-sergey@inbox.ru.
Maria A KhizhnyakovaLaboratory for Molecular Biology and NanoBiotechnology, Federal Research Center for Virology and Microbiology, Branch in Saratov, 410028 Saratov, Russia. ulianovaov@mail.ru.
Lidiya V SayapinaDepartment of Vaccine Control, Scientific Center on Expertise of Medical Application Products, 127051, Moscow, Russia. l.v.sayapina@mail.ru.
Onega V UlianovaLaboratory for Molecular Biology and NanoBiotechnology, Federal Research Center for Virology and Microbiology, Branch in Saratov, 410028 Saratov, Russia. ulianovaov@mail.ru.
Sergey S UlyanovDepartment for Medical Optics, Saratov State University, 410012, Saratov, Russia. prof.sergey.ulyanov@outlook.com.
Vladimir L MotinDepartment of Pathology, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA. vlmotin@utmb.edu.
State Research Center of Virology and Biotechnology VECTOR · RUFederal State Budgetary Institution "Center for Expertise and Quality Control of Medical Care" · RUSaratov State University · RUThe University of Texas Medical Branch at Galveston · US

Funding

Russian Academy of Sciences 0615-2018-0001
6 · The paper itself

Abstract

Omptins represent a family of proteases commonly found in various Gram-negative pathogens. These proteins play an important role in host-pathogen interaction and have been recognized as key virulence factors, highlighting the possibility of developing an omptin-based broad-spectrum vaccine. The prototypical omptin, His-tagged recombinant Pla, was used as a model target antigen. In total, 46 linear and 24 conformational epitopes for the omptin family were predicted by the use of ElliPro service. Among these we selected highly conserved, antigenic, non-allergenic, and immunogenic B-cell epitopes. Five epitopes (2, 6, 8, 10, and 11 corresponding to Pla regions 52-60, 146-150, 231-234, 286-295, and 306-311, respectively) could be the first choice for the development of the new generation of target-peptide-based vaccine against plague. The partial residues of omptin epitopes 6, 8, and 10 (regions 136-145, 227-230, and 274-285) could be promising targets for the multi-pathogen vaccine against a group of enterobacterial infections. The comparative analysis and 3D modeling of amino acid sequences of several omptin family proteases, such as Pla (

Indexed as

B-cell epitopebroad-spectrum vaccineGram-negative pathogensmulti-pathogen vaccineomptin family proteasespeptide ELISApeptide vaccinevaccine development

Identifiers

PMID30974891
PMCPMC6630670
OpenAlexW2937983569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.